Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
Mapping the Research Landscape of Immune Therapy for Endometrial Cancer
This systematic review uses a bibliometric analysis to map the landscape of immune checkpoint inhibitor research in endometrial cancer. The …
A large-scale analysis maps out how researchers worldwide are studying immune checkpoint inhibitors to treat endometrial cancer.
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma
Immunotherapy helps advanced head and neck cancer patients live longer
This systematic review and meta-analysis synthesized evidence on immunotherapy for head and neck squamous cell carcinoma. The authors report…
New analysis shows immune therapy helps advanced head and neck cancer patients survive longer when combined with other treatments
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
A systematic review and meta-analysis of real-world studies evaluated first-line pembrolizumab monotherapy for advanced NSCLC with high PD-L…
New data from thousands of patients shows pembrolizumab provides reliable long-term survival for advanced lung cancer without major safety s…
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
All pembrolizumab Articles
- Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
- Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
- Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
- PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
- Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma
- Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
- Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
- Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
- Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
- Sequential SBRT, pembrolizumab, and resection in oligometastatic colorectal cancer shows 60% 1-year RFS
- Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
- Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
- Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
- Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
- Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
- Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
- Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors
- Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
- Pembrolizumab adjuvant therapy trial for hepatocellular carcinoma recurrence-free survival
- Preclinical report suggests combined ARSB and pembrolizumab inhibits melanoma progression in mice
- Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
- Review: PD1/PDL1 spatial interactions predict pembrolizumab response in metastatic urothelial carcinoma
- Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
- Five medications including daptomycin and durvalumab show positive association with drug-induced eosinophilic pneumonia in database analysis
- Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
- Narrative review discusses immune checkpoint inhibitors in lung cancer patients
- Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
- Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
- Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
- Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
- Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
- Zanubrutinib-combined therapy in heavily treated non-GCB DLBCL: retrospective two-center cohort of 27 patients
- Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
- Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
- SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
- Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies
- FDA Approves Keytruda (pembrolizumab) for Treatment of Unresectable or Metastatic Melanoma
- Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
- Review synthesizes fungal immune evasion mechanisms and emerging immunotherapies for invasive fungal infections
- Regional motif diversity score in cfDNA predicts pembrolizumab response in head and neck cancer
- Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
- Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
- Pilot qualitative study explores pathways and acceptability of cash transfers for low-income patients with hypertension or diabetes
- Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
- Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
- Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
- Phase 2 trial links early monocyte elevation to response in gastric cancer immunotherapy
- Pembrolizumab ranks highest for survival in cervical cancer network meta-analysis
- Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
- Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
- PD-1 inhibitors + chemo improve OS, PFS, ORR in first-line advanced ESCC; benefit limited in PD-L1 CPS <1
- Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC
- Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
- Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
- Low sADC Predicts Poor Outcomes in Cervical Cancer with PD-1 Inhibitors
- Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients